Upgrade Alert for AMAG Pharmaceuticals (AMAG)
AMAG Pharmaceuticals (NASDAQ:AMAG) was upgraded from Neutral to Outperform at RW Baird today. The stock closed yesterday at $20.69 on volume of 259,000 shares, above average daily volume of 97,000.
AMAG Pharmaceuticals, Inc., a biopharmaceutical company, utilizes its proprietary nanoparticle technology for the development and commercialization of therapeutic iron compounds to treat anemia and novel imaging agents to aid in the diagnosis of cancer and cardiovascular disease.
There is potential upside of 15.3% for shares of AMAG Pharmaceuticals based on a current price of $20.69 and an average consensus analyst price target of $23.86. The stock should find initial resistance at its 200-day moving average (MA) of $21.12 and further resistance at its 50-day MA of $23.09.
AMAG Pharmaceuticals share prices have moved between a 52-week high of $27.00 and a 52-week low of $13.85 and closed yesterday at 49% above that low price at $20.69 per share. Over the past week, the 200-day moving average (MA) has gone up 0.4% while the 50-day MA has declined 1.3%.
SmarTrend recommended that its subscribers protect gains by selling shares of AMAG Pharmaceuticals on September 26th, 2013 by issuing a Downtrend alert when the shares were trading at $22.53. Since that call, shares of AMAG Pharmaceuticals have fallen 8.2%. We are now looking for when a new Uptrend will commence and will alert SmarTrend subscribers in real time.
Keywords: analyst upgrades/downgrades amag pharmaceuticals